CHINA RESOLUTE INTEGRITY STUDY Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use --A Prospective, Multi-center, Single Arm, Non-randomized Study

Trial Profile

CHINA RESOLUTE INTEGRITY STUDY Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use --A Prospective, Multi-center, Single Arm, Non-randomized Study

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Arteriosclerosis; Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders
  • Focus Therapeutic Use
  • Acronyms CHINA RESOLUTE INTEGRITY STUDY; CV-Resolute Integrity China
  • Sponsors Medtronic
  • Most Recent Events

    • 20 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 24 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top